Related Experiment Video

Updated: Mar 29, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia

Musa Yilmaz1, Elias Jabbour2

  • 1Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX.

Seminars in Oncology
|November 29, 2015
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment. While no TKI offers survival superiority, achieving deeper responses with TKIs improves outcomes, and treatment-free remission is possible for some.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myeloid leukemia (CML) management has been revolutionized by tyrosine kinase inhibitors (TKIs).
  • Several TKIs, including imatinib, nilotinib, and dasatinib, are approved for newly diagnosed CML.
  • Choosing the optimal TKI presents a challenge due to the lack of demonstrated survival superiority among available options.

Purpose of the Study:

  • To review the current landscape of TKI therapy in CML management.
  • To discuss factors influencing TKI selection, treatment monitoring, and discontinuation strategies.
  • To explore the potential for treatment-free remission and cure in CML.

Main Methods:

  • Review of clinical studies and guidelines on TKI therapy for CML.
  • Analysis of response rates, survival advantages, and side effect profiles of different TKIs.
  • Examination of criteria and outcomes for TKI discontinuation and treatment-free remission.

Main Results:

  • Second-generation TKIs demonstrate higher rates of deeper and earlier responses compared to imatinib.
  • Improved treatment response, irrespective of TKI type, is associated with a survival advantage.
  • Treatment-free remission is achievable in select CML patients, but discontinuation outside clinical trials is not recommended due to data limitations.

Conclusions:

  • TKI selection should consider response rates, side effect profiles, and cost.
  • Close patient monitoring and timely treatment adjustments are crucial for optimal CML management.
  • While TKIs offer significant advancements, further research is needed to establish long-term outcomes and consensus on discontinuation protocols.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
640